

## Therapie der renalen Anämie – mit welchem Ziel?

K.-U. Eckardt

aus BDI aktuell 12/2007

- 1** Astor BC, Mutner P, Levin A, Eustace JA, Coresh J. **Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988 - 1994).** Arch Intern Med 2002; 162: 1401-1408
- 2** Besarab A, Bolton WK, Browne JK. et al. **The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin.** N Engl J Med 1998; 339: 584-590
- 3** Drueke TB, Locatelli F, Clyne N. et al. **Normalization of hemoglobin level in patients with chronic kidney disease and anemia.** N Engl J Med 2006; 355: 2071-2084
- 4** Eckardt KU. **Cardiovascular consequences of renal anaemia and erythropoietin therapy.** Nephrol Dial Transplant 1999; 14: 1317-1323
- 5** Eschbach J, Egrie JC, Downing MR, Browne JK, Adamson JW. **Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.** N Engl J Med 1987; 316: 73-78
- 6** Ezekowitz JA. et al. **Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.** Circulation 2003; 107: 223-225
- 7** Hahn EA, Cella D, Chassany O, Fairclough DL, Wong GY, Hays RDA. **Comparison of the Precision of Health-Related Quality of Life Data Relative to Other Clinical Measures.** Mayo ClinProc 2007; in press:
- 8** Hörl W. **Clinical aspects of iron use in the anemia of kidney disease.** J Am Soc Nephrol 2007; 18: 382-393
- 9** Macdougall I, Eckardt KU. **Novel strategies for stimulating erythropoiesis and potential new treatments for anemia.** Lancet 2006; 368: 947-953
- 10** Mix TC, Brenner RM, Cooper ME. et al. **Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.** Am Heart J 2005; 149: 408-413
- 11** Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. **Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.** Kidney Int 2004; 66: 1131-1138
- 12** Nangaku M, Eckardt KU. **Pathogenesis of renal anemia.** Semin Nephrol 2006; 26: 261-268
- 13** National Kidney Foundation. **KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin targets.** Am J Kidney Dis 2007; in preparation:
- 14** Ofsthun N, Labrecque J, Lacson E. et al. **The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.** Kidney Int 2003; 63: 1908-1914
- 15** Parfrey PS, Foley RN, Wittreich BH. et al. **Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.** J Am Soc Nephrol 2005; 16: 2180-2189
- 16** Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, Levey AS. **Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study.** J Am Coll Cardiol 2002; 40: 27-33
- 17** Singh AK, Szczech L, Tang KL. et al. **Correction of anemia with epoetin alfa in chronic kidney disease.** N Engl J Med 2006; 355: 2085-2098
- 18** Volkova N, Arab L. **Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients.** Am J Kidney Dis 2006; 47: 24-36